Managing Hospitalized Patients Taking SGLT2 Inhibitors: Reducing the Risk of Euglycemic Diabetic Ketoacidosis
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are emerging as an important therapy not only for type 2 diabetes (T2DM), but also for heart disease and kidney disease. As these medicines gain acceptance, the number of hospitalized patients receiving them is likely to rise. During clinical trials,...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2023-02-01
|
| シリーズ: | Diabetology |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/2673-4540/4/1/10 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|